Structural requirements of taxoids for nitric oxide and tumor necrosis factor production by murine macrophages. 1996

T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
Department of Microbiology, Jichi Medical School, Tochigi-ken, Japan. tkirikae@jichi.ac.jp

Taxol (paclitaxel), a microtubule stabilizer with antitumor activity, mimics the actions of lipopolysaccharide (LPS) on murine macrophages (M phi). In the present study, a variety of synthetic analogs of paclitaxel were examined for their potencies to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by peritoneal M phi from LPS-responsive C3H/HeN, and LPS-hyporesponsive C3H/HeJ mice, and by M phi-like LPS-responsive J774.1 and its mutant LPS-hyporesponsive J7.DEF3 cells. In this structure-activity relationship study, we found that (i) the benzoyl group at the C-3' position of paclitaxel is the most important site to activate C3H/HeN M phi; (ii) the phenyl group at C-3' is not a requisite for the activity; (iii) there is good correlation between NO and TNF production by the M phi in response to compounds, except for the analogs having a tert-butoxycarbonyl (10-acetyldocetaxel) or a thiophene-2-carbonyl group at C-3'-N instead of a benzoyl group, which is more dominant in TNF than in NO production; (iv) the compounds tested induce neither NO nor TNF production by C3H/HeJ M phi; (v) active compounds to C3H/He M phi induce TNF production by J7.DEF3 cells as well as J774.1 cells; and (vi) there is no correlation between the NO/TNF inducibility to C3H/HeN M phi and growth inhibitory activity against M phi-like J774.1 and J7.DEF3 cells. These data also suggest that the binding of taxoid/LPS to tubulin is not essential for the M phi activation.

UI MeSH Term Description Entries
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D017737 Macrophages, Peritoneal Mononuclear phagocytes derived from bone marrow precursors but resident in the peritoneum. Peritoneal Macrophages,Macrophage, Peritoneal,Peritoneal Macrophage
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
September 1996, The Journal of infectious diseases,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
July 1999, International journal of immunopharmacology,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
December 1996, The Journal of infectious diseases,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
January 1999, Microbiology and immunology,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
October 2002, Journal of ethnopharmacology,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
November 1998, FEMS immunology and medical microbiology,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
April 1997, The Journal of infectious diseases,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
January 1989, The Journal of infectious diseases,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
June 2003, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP,
T Kirikae, and I Ojima, and F Kirikae, and Z Ma, and S D Kuduk, and J C Slater, and C S Takeuchi, and P Y Bounaud, and M Nakano
August 2002, Clinica chimica acta; international journal of clinical chemistry,
Copied contents to your clipboard!